Vincenzo Scattoni
Research Subjects
Research Interests
Vincenzo Scattoni has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Francesco Montorsi
Department of Urology, University Vita-Salute, Scientific Institute San Raffaele, Milan
19 shared publicationsPatrizio Rigatti
17 shared publications- Marco Roscigno
Department of Urology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy
15 shared publications Carmen Maccagnano
Casa di Cura Capitanio (Auxologico)
12 shared publicationsMassimo Freschi
12 shared publicationsMarco Raber
7 shared publications
Latest Publications
- 7 May 2025
- Published by Springer Nature
- p. 253-263
Benign Prostatic Hypertrophy
- 7 May 2025
- Published by Springer Nature
- p. 207-220
Prostate and Seminal Vesicles: Ultrasound Anatomy and Scanning Methods
- 7 May 2025
- Published by Springer Nature
- p. 207-220
Prostate and Seminal Vesicles: Ultrasound Anatomy and Scanning Methods
- 7 May 2025
- Published by Springer Nature
- p. 701-711
US Contrast Media in Prostatic Disease
- 7 May 2025
- Published by Springer Nature
- p. 347-359
Interventional Ultrasound: Prostatic Biopsy with Special Techniques (Saturation, Template)
- 7 May 2025
- Published by Springer Nature
- p. 347-359
Interventional Ultrasound: Prostatic Biopsy with Special Techniques (Saturation, Template)
- 7 May 2025
- Published by Springer Nature
- p. 361-370
Transperineal and Transrectal Biopsy Techniques in Men on Active Surveillance for Early Prostate Cancer
- 7 May 2025
- Published by Springer Nature
- p. 361-370
Transperineal and Transrectal Biopsy Techniques in Men on Active Surveillance for Early Prostate Cancer
- 29 March 2017
- Published by Springer Nature
- p. 617-628
US Contrast Media in Prostatic Disease
- 29 March 2017
- Published by Springer Nature
- p. 343-357
Interventional Ultrasound: Prostatic Biopsy with Special Techniques (Saturation, Template)
- 29 March 2017
- Published by Springer Nature
- p. 343-357
Interventional Ultrasound: Prostatic Biopsy with Special Techniques (Saturation, Template)
- 29 March 2017
- Published by Springer Nature
- p. 281-291
Benign Prostatic Hypertrophy
- 29 March 2017
- Published by Springer Nature
- p. 233-247
Prostate and Seminal Vesicles: Ultrasound Anatomy and Scanning Methods
- 29 March 2017
- Published by Springer Nature
- p. 233-247
Prostate and Seminal Vesicles: Ultrasound Anatomy and Scanning Methods
- 10 February 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (2) , 413-424
Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights
Aim: To present a summary of the updated guidelines of the Italian Prostate Biopsies Group following the best recent evidence of the literature. Materials and Methods: A systematic review of the new data emerging from 2012-2015 was performed by a panel of 14 selected Italian experts in urology, pathology and radiology. The experts collected articles published in the English-language literature by performing a search using Medline, EMBASE and the Cochrane Library database. The articles were evaluated using a systematic weighting and grading of the level of the evidence according to the Grading of Recommendations Assessment, Development and Evaluation framework system. Results: An initial prostate biopsy is strongly recommended when i) prostate specific antigen (PSA) >10 ng/ml, ii) digital rectal examination is abnormal, iii) multiparametric magnetic resonance imaging (mpMRI) has a Prostate Imaging Reporting and Data System (PIRADS) ≥4, even if it is not recommended. The use of mpMRI is strongly recommended only in patients with previous negative biopsy. At least 12 cores should be taken in each patient plus targeted (fusion or cognitive) biopsies of suspicious area (at mpMRI or transrectal ultrasound). Saturation biopsies are optional in all settings. The optimal strategy for reducing infection complications is still a controversial topic and the instruments to reduce them are actually weak. The adoption of Gleason grade groups in adjunction to the Gleason score when reporting prostate biopsy results is advisable. Conclusion: These updated guidelines and recommendations are intended to assist physicians and patients in the decision-making regarding when and how to perform a prostatic biopsy.
- 10 February 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (2) , 413-424
Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights
Aim: To present a summary of the updated guidelines of the Italian Prostate Biopsies Group following the best recent evidence of the literature. Materials and Methods: A systematic review of the new data emerging from 2012-2015 was performed by a panel of 14 selected Italian experts in urology, pathology and radiology. The experts collected articles published in the English-language literature by performing a search using Medline, EMBASE and the Cochrane Library database. The articles were evaluated using a systematic weighting and grading of the level of the evidence according to the Grading of Recommendations Assessment, Development and Evaluation framework system. Results: An initial prostate biopsy is strongly recommended when i) prostate specific antigen (PSA) >10 ng/ml, ii) digital rectal examination is abnormal, iii) multiparametric magnetic resonance imaging (mpMRI) has a Prostate Imaging Reporting and Data System (PIRADS) ≥4, even if it is not recommended. The use of mpMRI is strongly recommended only in patients with previous negative biopsy. At least 12 cores should be taken in each patient plus targeted (fusion or cognitive) biopsies of suspicious area (at mpMRI or transrectal ultrasound). Saturation biopsies are optional in all settings. The optimal strategy for reducing infection complications is still a controversial topic and the instruments to reduce them are actually weak. The adoption of Gleason grade groups in adjunction to the Gleason score when reporting prostate biopsy results is advisable. Conclusion: These updated guidelines and recommendations are intended to assist physicians and patients in the decision-making regarding when and how to perform a prostatic biopsy.